MUC16: clinical targets with great potential

Clin Exp Med. 2024 May 17;24(1):101. doi: 10.1007/s10238-024-01365-5.

Abstract

Mucin 16 (MUC16) is a membrane-bound mucin that is abnormally expressed or mutated in a variety of diseases, especially tumors, while being expressed in normal body epithelium. MUC16 and its extracellular components are often important cancer-related biomarkers. Abnormal expression of MUC16 promotes tumor progression through mesenchymal protein, PI3K/AKT pathway, JAK2/STAT3 pathway, ERK/FBW7/c-Myc, and other mechanisms, and plays an important role in the occurrence and development of tumors. In addition, MUC16 also helps tumor immune escape by inhibiting T cells and NK cells. Many drugs and trials targeting MUC16 have been developed, and MUC16 may be a new direction for future treatments. In this paper, the mechanism of action of MUC16 in the development of cancer, especially in the immune escape of tumor, is introduced in detail, indicating the potential of MUC16 in clinical treatment.

Keywords: Biomarker; CA125; Clinical trials; Immune escape; Mucin 16 (MUC16).

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • CA-125 Antigen* / metabolism
  • Humans
  • Membrane Proteins / metabolism
  • Molecular Targeted Therapy
  • Neoplasms* / metabolism
  • Signal Transduction
  • Tumor Escape

Substances

  • MUC16 protein, human